Latest News for: gimv
Edit
Cegeka Appoints Koen Deryckere as New Chief Executive Officer (GIMV NV)
Public Technologies 23 Feb 2026
). Cegeka Group today announced the appointment of Koen Deryckere as its new Chief Executive Officer (CEO) ... Koen Deryckere said ... GIMV NV published this content on February 23, 2026, and is solely responsible for the information contained herein ... (noodl.
Edit
Announcement of share buyback in the context of a share purchase plan (GIMV NV)
Public Technologies 20 Feb 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on February 20, 2026, and is solely responsible for the information contained herein ...
Edit
Aankondiging inkoop eigen aandelen in het kader van een aandelenaankoopplan (GIMV NV)
Public Technologies 20 Feb 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on February 20, 2026, and is solely responsible for the information contained ...
Edit
Gimv zet sterk groeitraject voort met solide resultaten Recordinvesteringen in boekjaar van 9 maanden (GIMV NV)
Public Technologies 19 Feb 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on February 19, 2026, and is solely responsible for the information contained ...
Edit
Gimv builds on strong growth to deliver solid results Record investment level in a shortened financial year of 9 months (GIMV NV)
Public Technologies 19 Feb 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on February 19, 2026, and is solely responsible for the information contained ...
Edit
Gimv increases focus on strategic objectives and discontinues activities for new Life Sciences investments (GIMV NV)
Public Technologies 26 Jan 2026
In line with its strategic priorities and growth ambitions, the board of directors of Gimv has decided to focus on investments and value creation in Anchor and in the following four investment platforms.
Edit
Gimv verhoogt focus op strategische doelstellingen en discontinueert activiteiten voor nieuwe Life Sciences investeringen (GIMV NV)
Public Technologies 26 Jan 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on January 26, 2026, and is solely responsible for the information contained ...
Edit
Gimv leidt een Series B investeringsronde van EUR 51 miljoen in Exciva voor verdere ontwikkeling van een innovatieve Alzheimerbehandeling (GIMV NV)
Public Technologies 20 Jan 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on January 20, 2026, and is solely responsible for the information contained ...
Edit
Gimv leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy (GIMV NV)
Public Technologies 20 Jan 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on January 20, 2026, and is solely responsible for the information contained ...
Edit
Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT
Pharmiweb 20 Jan 2026
Gimv and EQT Life Sciences co-led the round ... (EQT Life Sciences), Andreas Jurgeit (Gimv), Aidan King (Fountain Healthcare), Vikram Sudarsan (independent Board member) and François Conquet (CEO).
Edit
Gimv sells majority stake in ALT Technologies to CCL Industries (GIMV NV)
Public Technologies 16 Jan 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on January 16, 2026, and is solely responsible for the information contained ...
Edit
Gimv verkoopt meerderheidsbelang in ALT Technologies aan CCL Industries (GIMV NV)
Public Technologies 16 Jan 2026
GIMV ... Gimv ... GIMV ... GIMV NV published this content on January 16, 2026, and is solely responsible for the information contained ...
Edit
Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors (GIMV NV)
Public Technologies 12 Jan 2026
) ... The study has received regulatory approval in the United States and Australia ... Kivu is headquartered in San Mateo, CA ... Media Contact ... GIMV NV published this content on January 12, 2026, and is solely responsible for the information contained herein.
Edit
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases (GIMV NV)
Public Technologies 12 Jan 2026
Bram Vanparys, Managing Director - Head of Life Sciences at Gimv comments ... and Gimv ... GIMV NV published this content on January 12, 2026, and is solely responsible for the information contained herein.
Edit
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD (GIMV NV)
Public Technologies 08 Jan 2026
). FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration ... GIMV NV published this content on January 08, 2026, and is solely responsible for the information contained herein ... (noodl.
- 1
- 2
- Next page »